Organon Arixtra Anti-Thrombotic Could Clear FDA By Mid-August
Organon's anti-thrombotic agent Arixtra could receive approval from FDA in mid-August, Organon President Hans Vemer told the Goldman Sachs healthcare conference June 12 in Dana Point, Calif.
You may also be interested in...
Sanofi-Synthelabo is increasing its role in the co-promotion of Avapro ahead of Bristol-Myers Squibb's resubmission of the NDA for Vanlev.
Patients treated with Sanofi-Synthelabo/Organon's pentasaccharide compound SR 90107 have 50% fewer venous thromboembolic events than those on enoxaparin (Aventis' Lovenox), Sanofi-Synthelabo reported at a meeting with the financial community in London Sept. 6.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011